Related Experiment Video
Updated: Jun 21, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.2K
Biomarker-driven molecular imaging probes in radiotherapy
Haonan Li1, Qiyong Gong1,2,3, Kui Luo1,2
1Department of Radiology, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China.
Theranostics
|July 12, 2024
Summary
Molecular imaging probes are crucial for precision radiotherapy, enabling monitoring of biomarkers. Further validation of imaging biomarkers and probe designs is needed for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Radiotherapy
- Molecular Imaging
Background:
- Biomarker-driven molecular imaging is key in precision radiotherapy.
- Molecular imaging probes, including nanoprobes, monitor biomarker distribution for cancer treatment.
Purpose of the Study:
- To review clinically-investigated biomarkers for radiotherapy.
- To examine the role of molecular imaging probes in radiotherapy.
- To propose future research directions.
Main Methods:
- Literature review of preclinical studies and clinical trials.
- Analysis of imaging biomarkers and molecular imaging probes in radiotherapy.
- Synthesis of findings and future perspectives.
Main Results:
- Few imaging biomarkers are validated for radiotherapeutic outcomes or toxicities.
- Activatable molecular imaging probes show promise in early studies for precision radiotherapy.
- Ongoing research explores numerous imaging biomarkers.
Conclusions:
- Biomarker-driven molecular imaging probes are essential for precision radiotherapy.
- Validation of imaging biomarkers and probe design requires extensive investigation.
- Multi-center collaboration is needed to correlate biomarkers with treatment outcomes and toxicities.
